Skip to main content
SpringerLink
Log in

Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs

  • Research Letter
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

References

  1. Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Expert Rev Pharmacoeconomcis Outcomes Res 2008; 8: 357–71

    Article  Google Scholar 

  2. Wettermark B, Godman B, Andersson K, et al. Recent national and regional drug reforms in Sweden: implications for pharmaceutical companies in Europe. Pharmacoeconomics 2008; 26: 537–50

    Article  PubMed  Google Scholar 

  3. Godman B, Haycox A, Schwabe U, et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 2008; 26:91–8

    Article  PubMed  Google Scholar 

  4. Godman B, Wettermark B, Hoffman M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoeconomcis Outcomes Res 2009; 9: 65–83

    Article  Google Scholar 

  5. Beishon J, McBride T. Scharaschkin S. et al. National Audit Office. Prescribing costs in primary care. 14 May 2007 [online]. Available from URL: http://www.nao.org.uk [Accessed 2007 May 21]

  6. Simoens S. Trends in generic prescribing and dispensing in Europe. Expert Rev Clin Pharmacol 2008; 1: 497–503

    Article  Google Scholar 

  7. Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth 2006; 12: 15–7

    Google Scholar 

  8. van Ganse E, Chambea G, Becquart B. et al. France: pharmaceutical pricing and reimbursement information, October 2007 [online]. Available from URL: http://ppri.oebig.at/Downloads/Results/France_PPRI_2007.pdf [Accessed 2008 Sep 20]

  9. Paris V. Pharmaceutical regulation in France 1980–2003. Int J Health Plann Manage 2005; 20: 307–28

    Article  PubMed  Google Scholar 

  10. Kanavos P. Generic policies: rhetoric vs reality. Euro Observer 2008; 10: 1–6

    Google Scholar 

  11. Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for healthcare systems? Eurohealth 2008; 14: 18–22

    Google Scholar 

  12. Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J Generic Med 2006; 4: 4–14

    Article  Google Scholar 

  13. Dolezal T. Practical application of PE and HTA in Czech Republic November 2008 [online]. Available from URL: http://www.ceestahc.org/pliki/symp2008/dolezal.pdf [Accessed 2009 Feb 16]

  14. Busse R, Schreyögg J, Henke KD. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Int J Health Plann Manage 2005; 20: 329–49

    Article  PubMed  Google Scholar 

  15. Guidelines for ATC classification and DDD assignment 2006. Oslo: WHO Collaborating Centre for Drug Statistics Methodology [online]. Available from URL: http://www.whocc.no [Accessed 2009 Apr 9]

  16. Arzneiverordnungs Report 1999 to 2008. Springer Medizin Verlag Heildelberg [online]. Available from URL: http://www.springer.com/pharma/book/978-3-540-69218-8 [Accessed 2009 Jan 19]

  17. Wessling A, Lundin D. The review of drugs against disease caused by acid stomach: a summary. Solna: Pharmaceuticals Benefits Board, 2006 [online]. Available from URL: http://www.tlv.se/upload/genomgangen/summary-stomach-acid.pdf [Accessed 2009 Mar 6]

  18. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 2008; 336: 2–3

    Article  PubMed  Google Scholar 

  19. Björnsson E, Abrahssom H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24: 945–54

    Article  PubMed  Google Scholar 

  20. Yang YY, Lewis J, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296 (24): 2947–53

    Article  PubMed  CAS  Google Scholar 

  21. Walley T, Folino-Gallo P, Schwabe U, et al., on behalf of the EuroMedStat Group. Variations and increase in use of statins across Europe: data from administrative databases. BMJ 2004; 328: 385–6

    Article  PubMed  Google Scholar 

  22. Pfizer criticises SORTIS reference prices: Ministry of Health recommends change. Handelsblatt 2004 Nov 8 [online]. Available from URL: http:www.handelsblatt.com/archive/pfizer-kritisiert-sortis-festbetrag-ministerium-raet-zum-wechsel;816275 [Accessed 2009 Jan 19]

  23. Kastelein J, Akdim F, Stroes E, et al. Simvastatin with or without ezetimibe in familial hypercholesterolaemia. N Engl J Med 2008; 358 (14): 1431–43

    Article  PubMed  CAS  Google Scholar 

  24. Brown GB, Taylor A. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med 2008; 358 (14): 1504–7

    Article  PubMed  CAS  Google Scholar 

  25. Alonso PW. Vytorin support statement raises questions over American Heart Association funding. 2008 Jan 24 [online]. Available from URL: http://www.yourlawyer.com/articles/read/13745 [Accessed 2009 May 9]

  26. Saul S. Heart group backs drug made by Ally. New York Times 2008 Jan 24 [online]. Available from URL: http://www.nytimes.com/2008/01/24/business/24heart.html?_r=1 [Accessed 2009 May 9]

  27. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359 (13): 1343–56

    Article  PubMed  Google Scholar 

  28. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008; 359 (13): 1357–66

    Article  PubMed  CAS  Google Scholar 

  29. Alsheikh-Ali A, Karas R. Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: a post-marketing analysis. Jn Clinical Lipidology 2009; 3 (2): 138–42

    Article  Google Scholar 

  30. Jack A. Balancing big pharma’s books. BMJ 2008; 336: 418–9

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist with the preparation of this letter. The authors have no conflicts of interest that are directly relevant to the content of this letter.

The authors acknowledge the help of Arash Ghaffarian, University of Uppsala, with the analysis.

Author information

Authors and Affiliations

  1. Institute for Pharmacological Research ‘Mario Negri’, Milan, Italy

    Brian Godman

  2. Prescribing Research Group, University of Liverpool Management School, Liverpool, UK

    Brian Godman

  3. Institute of Pharmacology, Ruprecht-Karls University Heidelberg, Heidelberg, Germany

    Ulrich Schwabe

  4. AOK Research Institute, Berlin, Germany

    Gisbert Selke

  5. Regional Drug Experts LÄKSAK, Department of Drug Management and Informatics, Stockholm County Council, Stockholm, Sweden

    Björn Wettermark

  6. Department of Laboratory Medicine, Division of Clinical Pharmacology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden

    Björn Wettermark

Authors
  1. Brian Godman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gisbert Selke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Björn Wettermark
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Godman, B., Schwabe, U., Selke, G. et al. Update of Recent Reforms in Germany to Enhance the Quality and Efficiency of Prescribing of Proton Pump Inhibitors and Lipid-Lowering Drugs. Pharmacoeconomics 27, 435–438 (2009). https://doi.org/10.2165/00019053-200927050-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200927050-00010

Keywords

Search

Navigation